The period of pharmaceutical development known as the “me-too drug” or “follow-on drug” era was not the most auspicious for the sector. One pharmaceutical company’s small molecule drug was closely followed to market by a very similar product from another company. Medicinal chemists would make the slightest change that effectively left safety and efficacy as close to the initial drug as possible while skirting around the originator’s patents. The histamine H2 receptor antagonists Zantac (ranitidine) and Tagamet (cimetidine) – from the component companies of GSK plc* – for the treatment of gastric ulcers, and the first tyrosine kinase inhibitors (TKIs) Tarceva (erlotinib) from Roche Holding AG and Iressa (gefitinib) from AstraZeneca PLC for the treatment of non-small cell lung cancer (NSCLC) were two examples of close chemical relations.
Although small molecules continue to be developed, there now appears to be less scope for this follow-on drug development, probably because more comprehensive related structures are included in patent filings
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?